跳转至内容
Merck

SML2633

Sigma-Aldrich

Sorafenib tosylate

≥98% (HPLC)

别名:

4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, 4-methylbenzenesulfonate, BAY 43-9006 tosylate salt, BAY43-9006 tosylate salt, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea, 4-methylbenzenesulfonate

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H16ClF3N4O3·C7H8SO3
分子量:
637.03
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77
价格与库存信息目前不能提供

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to very dark brown

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES字符串

FC(F)(F)c2c(ccc(c2)NC(=O)Nc3ccc(cc3)Oc4cc(ncc4)C(=O)NC)Cl.[S](=O)(=O)([O-])c1ccc(cc1)C.[H+]

InChI

1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)

InChI key

IVDHYUQIDRJSTI-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

Orally active kinase inhibitor that exerts anticancer efficacy via targeting Raf-1 (c-Raf), b-Raf, VEGFR-2 (Flk-1, KDR), VEGFR-3, PDGFR-β, Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.
Tosylate salt of the orally active kinase inhibitor Sorafenib (BAY 43-9006) that exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-β), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

象形图

Health hazardEnvironment

警示用语:

Danger

危险分类

Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Agnieszka Karbownik et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 130, 110530-110530 (2020-07-28)
Sorafenib (SR) is one of the most potent UGT (1A1, 1A9) inhibitors (in in vitro tests). The inhibition of UGT1A1 may cause hyperbilirubinaemia, whereas the inhibition of UGT1A9 and 1A1 may result in drug-drug interactions (DDIs). Tapentadol (TAP) is a
Pan Liang et al.
International journal of pharmaceutics, 583, 119375-119375 (2020-04-29)
A novel nanocrystals delivery system of parthenolide (PTL) was designed to combined application with sorafenib (Sora) for advanced hepatocellular carcinoma (HCC) therapy, attempting to not only improve the poor aqueous solubility of PTL, but also enhance the synergistic therapeutic effects
Şükran Alpdemir et al.
IET nanobiotechnology, 14(7), 617-622 (2020-10-04)
This study aimed to develop sorafenib loaded magnetic microspheres for the treatment of hepatocellular carcinoma. To achieve this goal, superparamagnetic iron oxide nanoparticles (SPIONs) were synthesised and encapsulated in alginate microspheres together with an antineoplastic agent, sorafenib. In the study
Qiaolin Li et al.
Cancer letters, 496, 169-178 (2020-09-29)
Nanoparticle-based photothermal ablation (PTA) has been intensively investigated recently. However, the poor biocompatibility of most PTA agents and potential long-term toxicity obstruct their clinical translation. Meanwhile, previous PTA studies are limited to surface tumors because of insufficient light penetration depth
Jonathan O Rayner et al.
Biochemical pharmacology, 182, 114227-114227 (2020-09-24)
AR12 is a derivative of celecoxib which no-longer acts against COX2 but instead inhibits the ATPase activity of multiple chaperone proteins, in particular GRP78. GRP78 acts as a sensor of endoplasmic reticulum stress and is an essential chaperone required for

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门